COMMUNICATION
News & Press Release
Total 122
-
32Researchers in Korea Develop Dementia Drugs...Clinical Trial Promotion.
DATE : 2022-10-19
VIEW : 2645
-
31Neurobiogen, a candidate for new drugs for Alzheimer's, Phase 1 Clinical Treatment.
DATE : 2022-03-03
VIEW : 2812
-
30Clinical approval of Neurobiogen's reversible Maobi inhibitor'.
DATE : 2022-03-03
VIEW : 2831
-
29Neurobiogen 'New Drug to Treat Brain Diseases' Approved for Phase 1 Clinical Treatment in Korea.
DATE : 2022-03-02
VIEW : 2736
-
28Neurobiogen, MAO-B Target Dementia Clinic Phase 1 Authorization.
DATE : 2022-03-02
VIEW : 2830
-
27Neurobiogen Proposes Possible Treatment of New Drug Substance 'KDS2010' Parkinson's Disease.
DATE : 2021-10-14
VIEW : 2841
-
26Neurobiogen, New Drug Candidate Material KDS2010 Proposes Possible Treatment of Parkinson's Disease.
DATE : 2021-10-12
VIEW : 2827
-
25Neurobiogen, suggesting the possibility of treating Parkinson's disease.
DATE : 2021-10-12
VIEW : 3251
-
24Neurobiogen Proposes Possible Treatment of New Drug Substance 'KDS2010' Parkinson's Disease.
DATE : 2021-10-12
VIEW : 2930
-
23Kim Sang-wook, CEO of Neurobiogen, said, "Our Alzheimer's treatment has a different target in itself
DATE : 2021-10-05
VIEW : 2947
- Add(06714) 2 FL, Bangbae BLDG, 9, Myeongdal-ro, Seocho-gu, Seoul, Republic of Korea
- Tel+82-70-4018-8009
- Fax+82-02-3486-2613
- E-mailneuro_reply@neurobiogen.com
FAMILY SITE
COPYRIGHT ⓒ 2025 NEUROBIOGEN. All rights reserved